PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Condition: Crohn Disease Interventions: Biological: TNFa Antagonist - Infliximab; Biological: TNFa Antagonist - Adalimumab; Biological: Anti-IL12/23 or anti-IL23 - Ustekinumab; Biological: Anti-IL12/23 or anti-IL23 - Risankizumab; Biological: Anti-integrin - Vedolizumab IV; Biological: Anti-integrin - Ved olizumab IV and SC Sponsors: University of Calgary; Alimentiv Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 3, 2023 Category: Research Source Type: clinical trials
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Condition: Crohn Disease Intervention: Drug: Infliximab Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2023 Category: Research Source Type: clinical trials
